magenta therapeutics is a biotechnology company harnessing the power of stem cell science to revolutionize stem cell transplantation for patients with immune- and blood-based diseases. by creating a platform focused on key areas of transplant medicine, magenta therapeutics is pioneering an integrated, but modular approach to stem cell therapies that reboot the blood and immune systems to create patient benefit. founded by internationally recognized leaders in stem cell transplant medicine, magenta therapeutics was launched in 2016 by third rock ventures and atlas venture and is headquartered in cambridge, mass. for more information, please visit www.magentatx.com.
Company profile
Ticker
DNTH
Exchange
Website
CEO
Jason Gardner
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Magenta Therapeutics, Inc.
SEC CIK
Corporate docs
Subsidiaries
Magenta Securities Corporation • Dianthus Therapeutics OpCo, Inc. ...
DNTH stock data
Latest filings (excl ownership)
EFFECT
Notice of effectiveness
28 Mar 24
S-8
Registration of securities for employees
21 Mar 24
S-1/A
IPO registration (amended)
21 Mar 24
10-K
2023 FY
Annual report
21 Mar 24
8-K
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY2023 Financial Results
21 Mar 24
S-1/A
IPO registration (amended)
7 Feb 24
8-K
Dianthus Therapeutics Announces $230 Million Private Placement
22 Jan 24
8-K
Results of Operations and Financial Condition
8 Jan 24
S-1/A
IPO registration (amended)
21 Dec 23
8-K
Other Events
21 Dec 23
Latest ownership filings
SC 13G/A
CITADEL ADVISORS LLC
14 Feb 24
SC 13G/A
5AM Partners VII, LLC
14 Feb 24
SC 13G/A
Third Rock Ventures IV, L.P.
14 Feb 24
SC 13G/A
GV 2016, L.P.
9 Feb 24
SC 13G
BCLS Fund III Investments, LP
2 Feb 24
SC 13G
RA CAPITAL MANAGEMENT, L.P.
2 Feb 24
SC 13D
Avidity Partners Management LP
31 Jan 24
4
EDWARD CARR
26 Jan 24
4
Adam M Veness
26 Jan 24
4
Simrat Randhawa
26 Jan 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 157.35 mm | 157.35 mm | 157.35 mm | 157.35 mm | 157.35 mm | 157.35 mm |
Cash burn (monthly) | (no burn) | (no burn) | 5.25 mm | 9.76 mm | (no burn) | 5.99 mm |
Cash used (since last report) | n/a | n/a | 31.43 mm | 58.42 mm | n/a | 35.84 mm |
Cash remaining | n/a | n/a | 125.92 mm | 98.93 mm | n/a | 121.51 mm |
Runway (months of cash) | n/a | n/a | 24.0 | 10.1 | n/a | 20.3 |
Institutional ownership, Q2 2022
13F holders | Current |
---|---|
Total holders | 75 |
Opened positions | 15 |
Closed positions | 32 |
Increased positions | 19 |
Reduced positions | 20 |
13F shares | Current |
---|---|
Total value | 145.65 mm |
Total shares | 51.83 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
TRV GP Iv | 6.76 mm | $8.11 mm |
Third Rock Ventures IV | 6.76 mm | $29.94 mm |
Deep Track Capital | 5.36 mm | $6.43 mm |
Atlas Venture Life Science Advisors | 3.48 mm | $4.17 mm |
JHG Janus Henderson | 3.00 mm | $3.57 mm |
Atlas Venture Fund X | 2.98 mm | $31.86 mm |
Casdin Capital | 2.42 mm | $2.90 mm |
Orbimed Advisors | 2.25 mm | $2.70 mm |
TCG Crossover Management | 2.12 mm | $2.55 mm |
Vanguard | 1.91 mm | $2.29 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
24 Jan 24 | Marino Garcia | Stock Option Common Stock | Grant | Acquire A | No | No | 17.88 | 275,000 | 4.92 mm | 275,000 |
24 Jan 24 | Ryan Savitz | Stock Option Common Stock | Grant | Acquire A | No | No | 17.88 | 120,000 | 2.15 mm | 120,000 |
24 Jan 24 | Simrat Randhawa | Stock Option Common Stock | Grant | Acquire A | No | No | 17.88 | 120,000 | 2.15 mm | 120,000 |
24 Jan 24 | Veness Adam M | Stock Option Common Stock | Grant | Acquire A | No | No | 17.88 | 110,000 | 1.97 mm | 110,000 |
24 Jan 24 | Carr Edward | Stock Option Common Stock | Grant | Acquire A | No | No | 17.88 | 80,000 | 1.43 mm | 80,000 |
News
Why Cutera Shares Are Trading Lower By Over 26%? Here Are Other Stocks Moving In Friday's Mid-Day Session
22 Mar 24
Worthington Steel Posts Upbeat Results, Joins Summit Midstream Partners, FedEx And Other Big Stocks Moving Higher On Friday
22 Mar 24
Wedbush Maintains Outperform on Dianthus Therapeutics, Raises Price Target to $33
22 Mar 24
Dianthus Therapeutics Q4 EPS $(0.71) Beats $(1.01) Estimate, Sales $457.00K Beat $310.00K Estimate
21 Mar 24
Decoding 4 Analyst Evaluations For Dianthus Therapeutics
15 Feb 24
Press releases
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY2023 Financial Results
21 Mar 24
Dianthus Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
7 Mar 24
Dianthus Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
23 Feb 24
Dianthus Therapeutics to Participate at the Guggenheim 6th Annual Biotechnology Conference
31 Jan 24
Dianthus Therapeutics Announces $230 Million Private Placement
22 Jan 24